BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

HHS’s public health emergency declaration on monkeypox prompts preparations
Now that the U.S. Department of Health and Human Services (HHS) has declared monkeypox a public health emergency, nearly two weeks after a similar declaration from the...

More in BioWorld

BioWorld MedTech

Bellaseno begins enrollment for resorbable breast implant trials
Bellaseno GmbH began recruiting patients in Australia for two clinical trials of its resorbable breast scaffold products on Aug. 4. The company expects to enroll 10...

More in BioWorld MedTech

BioWorld Science

AAIC 2022: The BACE1 inhibition comeback
Beta-site APP-cleaving enzyme 1 (BACE1) inhibitors have a long history of failure in patients with Alzheimer’s disease. Clinical development of verubecestat, elenbecestat, lanabecestat, umibecestat, atabecestat and LY-3202626 were all discontinued.

More in BioWorld Science

BioWorld Asia

Back for more: Sosei and Abbvie cut another $1B+ deal
Sosei Heptares and Abbvie Inc. have built on the huge, multitarget deal they cut a little more than two years ago by signing another one.

More in BioWorld Asia

BioWorld Insider Podcast

In Extending the human lifespan, a BioWorld special report, the team examined the latest science, the key biological drivers that can be targeted pharmacologically and the companies developing potential “Fountain of Youth” candidate drugs. In this episode of the BioWorld Insider Podcast, the team discussed the report’s highlights and key takeaways.